FOXP3 and rheumatoid arthritis: Percent inhibition by Foxp3 Treg cells was lower in the active RA (23.67%, range 8.15–46.72) as compared to the clinical remission group (57.24%, range 27.72–90.72) and healthy controls (64.18%, range 59.66–66.97), p < 0.0001 (95% CI 20.88–44.01) and p < 0.0001 (95% CI 33.54–47.30), respectively (Fig. 2B).